In the past week, SEEL stock has gone down by -59.69%, with a monthly decline of -56.68% and a quarterly plunge of -84.90%. The volatility ratio for the week is 13.69%, and the volatility levels for the last 30 days are 21.38% for Seelos Therapeutics Inc The simple moving average for the last 20 days is -61.08% for SEEL’s stock, with a simple moving average of -97.60% for the last 200 days.
Is It Worth Investing in Seelos Therapeutics Inc (NASDAQ: SEEL) Right Now?
The price-to-earnings ratio for Seelos Therapeutics Inc (NASDAQ: SEEL) is 0.01x, which is above its average ratio. Moreover, the 36-month beta value for SEEL is 1.84. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SEEL is 0.57M and currently, short sellers hold a 29.98% of that float. On October 15, 2024, SEEL’s average trading volume was 526.29K shares.
SEEL) stock’s latest price update
Seelos Therapeutics Inc (NASDAQ: SEEL) has experienced a decline in its stock price by -47.35 compared to its previous closing price of 2.45. However, the company has seen a fall of -59.69% in its stock price over the last five trading days. prnewswire.com reported 2024-10-15 that NEW YORK, Oct. 15, 2024 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on October 14, 2024, Seelos Therapeutics, Inc. (the “Company”) received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common stock from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with the minimum stockholder’s equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard Rule”). As previously disclosed, the Panel had provided the Company until October 11, 2024, to regain compliance with the Equity Standard Rule.
Analysts’ Opinion of SEEL
Many brokerage firms have already submitted their reports for SEEL stocks, with ROTH Capital repeating the rating for SEEL by listing it as a “Buy.” The predicted price for SEEL in the upcoming period, according to ROTH Capital is $8 based on the research report published on September 27, 2021 of the previous year 2021.
Guggenheim, on the other hand, stated in their research note that they expect to see SEEL reach a price target of $8. The rating they have provided for SEEL stocks is “Buy” according to the report published on July 01st, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to SEEL, setting the target price at $10 in the report published on June 01st of the previous year.
SEEL Trading at -66.89% from the 50-Day Moving Average
After a stumble in the market that brought SEEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.85% of loss for the given period.
Volatility was left at 21.38%, however, over the last 30 days, the volatility rate increased by 13.69%, as shares sank -66.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.12% lower at present.
During the last 5 trading sessions, SEEL fell by -62.25%, which changed the moving average for the period of 200-days by -99.35% in comparison to the 20-day moving average, which settled at $3.31. In addition, Seelos Therapeutics Inc saw -99.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SEEL starting from Golembiewski Michael Joseph, who purchase 83,000 shares at the price of $1.21 back on Nov 30 ’23. After this action, Golembiewski Michael Joseph now owns 86,450 shares of Seelos Therapeutics Inc, valued at $100,222 using the latest closing price.
Mehra Raj purchase 75,757 shares at $1.32 during a trade that took place back on Dec 01 ’23, which means that Mehra Raj is holding 185,142 shares at $99,999 based on the most recent closing price.
Stock Fundamentals for SEEL
Current profitability levels for the company are sitting at:
- -14.8 for the present operating margin
- 0.97 for the gross margin
The net margin for Seelos Therapeutics Inc stands at 2.03. The total capital return value is set at 1.06.
Based on Seelos Therapeutics Inc (SEEL), the company’s capital structure generated -0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -1.79. The debt to equity ratio resting at -0.36. The interest coverage ratio of the stock is -1296.0.
Currently, EBITDA for the company is -40.44 million with net debt to EBITDA at -0.33. When we switch over and look at the enterprise to sales, we see a ratio of 5.26. The receivables turnover for the company is 10.71for trailing twelve months and the total asset turnover is 0.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.08.
Conclusion
To wrap up, the performance of Seelos Therapeutics Inc (SEEL) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
